Large interindividual variability in the in vitro formation of tamoxifen metabolites related to the development of genotoxicity
Open Access
- 16 December 2003
- journal article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 57 (1) , 105-111
- https://doi.org/10.1046/j.1365-2125.2003.01970.x
Abstract
Aims To characterize the interindividual variability and the individual CYP involved in the formation of α‐hydroxy‐, N‐desmethyl‐ and N‐didesmethyl‐tamoxifen from tamoxifen. Methods Microsomes from 50 human livers were used to characterize the interindividual variability in the α‐hydroxylation, N‐desmethylation and N‐didesmethylation of tamoxifen. Selective inhibitors and recombinant enzymes were used to identify the forms of CYP catalysing these reactions. Results The rates of formation of α‐hydroxy‐, N‐desmethyl‐ and N‐didesmethyl‐tamoxifen were highly variable, and correlated with each other (P < 0.0001). The respective ranges were 0.7–11.4, 25.7–411, and below the limit of quantification – 4.4 pmol mg−1 protein min−1. Formation of all metabolites was observed with expressed recombinant CYP3A4, inhibited by troleandomycin (65, 77 and 35%, respectively, P < 0.05) and associated with CYP3A4 expression (rs = 0.612, rs = 0.585 and rs = 0.430, P < 0.01, respectively). Conclusions Formation of α‐hydroxy‐, N‐desmethyl‐ and N‐didesmethyl‐tamoxifen in vitro is highly variable and mediated predominantly by CYP3A4.Keywords
This publication has 20 references indexed in Scilit:
- Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNACarcinogenesis: Integrative Cancer Research, 2002
- Metabolism of Tamoxifen by Recombinant Human Cytochrome P450 Enzymes: Formation of the 4-Hydroxy, 4′-Hydroxy and N-Desmethyl Metabolites and Isomerization of trans-4-HydroxytamoxifenDrug Metabolism and Disposition, 2002
- The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z‐4‐hydroxy‐tamoxifen in human liverBritish Journal of Clinical Pharmacology, 2002
- Tamoxifen for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomesBritish Journal of Clinical Pharmacology, 1998
- Variable contribution of cytochromes p450 2d6, 2c9 and 3a4 to the 4-hydroxylation of tamoxifen by human liver microsomesBiochemical Pharmacology, 1997
- Effect of tamoxifen feeding on metabolic activation of tamoxifen by the liver of the Rhesus monkey: Does liver accumulation of inhibitory metabolities protect from tamoxifen-dependent genotoxicity and cancer?Carcinogenesis: Integrative Cancer Research, 1996
- Genotoxicity of tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450sCarcinogenesis: Integrative Cancer Research, 1994
- A current view of tamoxifen for the treatment and prevention of breast cancerBritish Journal of Pharmacology, 1993
- Identification of the cytochrome P450 IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomesBiochemical Pharmacology, 1991